Victoza

Overview

Victoza (liraglutide 1.8 mg) is a once-daily GLP-1 receptor agonist approved for type 2 diabetes. It was one of the first GLP-1 agonists to demonstrate cardiovascular benefit in the LEADER trial, establishing the cardiovascular safety and efficacy profile that has defined the GLP-1 class. While its weight loss effects are more modest than newer agents, it remains an important option in the diabetes treatment landscape.

Mechanism of Action

Identical mechanism to Saxenda — liraglutide activates GLP-1 receptors. At the 1.8 mg diabetes dose, the primary target is glycemic control. Appetite suppression and weight loss occur as secondary effects but are less pronounced than at the 3.0 mg weight-management dose.

Clinical Evidence

The LEADER trial demonstrated a 13% reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high cardiovascular risk — a landmark result when published in 2016. HbA1c reduction of 1.0–1.5% is typical, and mean weight loss at 1.8 mg in the labeled glycemic trials was 0.2 to 2.8 kg. LEADER positioned liraglutide as a cardiovascular-protective diabetes therapy.

Side Effects & Safety

Nausea, diarrhea, and vomiting are common but generally milder than at the higher Saxenda dose. Daily injection is required. Pancreatitis, gallbladder events, and thyroid C-cell tumor warnings apply.

FAQ